CEO Mark Capone talks about the primary challenges facing the molecular diagnostics industry and Myriad’s role as an industry leader in addressing these challenges.

Myriad Genetics at J.P. Morgan Healthcare Conference

Paul J. Diaz, president and chief executive officer, Bryan Riggsbee, chief financial officer, and Dale Muzzey, chief scientific officer, presented at the 41st annual J.P. Morgan (JPM) Healthcare Conference.